2012至2021年五个世界地区儿童和青少年2型糖尿病诊断时的频率与临床特征:来自SWEET登记处的数据
基于SWEET多国登记处2012至2021年的纵向观察性研究,在58170例新诊断糖尿病儿童和青少年中,2型糖尿病占4.8%(2819例)。2型糖尿病比例从2012/2013年的3.2%升至2020/2021年的6.0%,每两年相对增加9%(95%CI 5.9,12.3;p<0.001)。各地区比例差异大,欧洲最低、北美最高,且欧洲、澳大利亚/新西兰和北美观察到显著增加。
要点
- 2型糖尿病占新诊断儿童青少年糖尿病的4.8%(2819/58170)。
- 比例从2012/2013年3.2%升至2020/2021年6.0%,每两年相对增加9%(95%CI 5.9,12.3;p<0.001)。
- 各地区比例差异大,欧洲最低、北美最高,欧洲、澳大利亚/新西兰和北美显著增加。
核心结论
- 2012至2021年SWEET多国数据支持全球儿童青少年2型糖尿病增加,但存在地区差异。
- 该增加凸显全球需持续采取预防措施并提供可及的高级治疗方式。
研究设计与样本
- 基于SWEET登记处的纵向观察性研究,收集全球中心儿童青少年糖尿病的人口学和临床数据。
- 至2022年7月,SWEET登记处包括来自130个中心的96931人,共1154555次访视。
- 数据按地区分析:欧洲(EU)、澳大利亚和新西兰(AU/NZ)、南美洲(SA)、北美(NA)以及亚洲/中东和非洲(AS/AF)。
主要发现
- 总体2型糖尿病占新诊断糖尿病的4.8%(2819/58170):EU 614例、AU/NZ 293例、SA 79例、NA 1211例、AS/AF 622例。
- 2型糖尿病比例从2012/2013年的3.2%升至2020/2021年的6.0%,每两年相对增加9%(95%CI 5.9,12.3;p<0.001)。
- COVID-19大流行两年期间,2型糖尿病比例2020-2021年为6.0%,2018-2019年为5.4%。
- EU、AU/NZ和NA观察到2型糖尿病比例显著增加。
- 中位HbA1c最高为AS/AF 85 mmol/mol [9.9%](IQR 55-111 [7.2-12.3%]),最低为EU 63 mmol/mol [7.9%](IQR 48-99 [6.5-11.2%]);EU与NA(中位值73 mmol/mol [8.8%],IQR 50-105 [6.7-11.8%])差异有统计学意义(p=0.047)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: The diagnosis of type 2 diabetes is increasing in young people worldwide. This study evaluated the frequency and clinical characteristics of young people presenting with type 2 diabetes from the multinational SWEET e.V Registry 2012-2021, including the first years of the COVID-19 pandemic. METHODS: This is a longitudinal observational study based on the SWEET Registry, which collects demographic and clinical data on children and adolescents with diabetes from centres worldwide, with the diagnosis and classification of diabetes provided locally by each centre according to International Society for Paediatric and Adolescent Diabetes definitions. By July 2022, the SWEET Registry included 96,931 individuals from 130 centres with a total of 1,154,555 visits. Data were analysed by region: Europe (EU), Australia and New Zealand (AU/NZ), South America (SA), North America (NA) and Asia/Middle East and Africa (AS/AF). Trends in proportions for the two-year periods, calculated as cases with type 2 diabetes diagnoses over all cases with diabetes diagnoses, were estimated using logistic regression models adjusted for age at onset and sex. RESULTS: Overall, there were 2819 of 58,170 new cases (4.8%) with type 2 diabetes: 614 in EU, 293 in AU/NZ, 79 in SA, 1211 in NA and 622 in AS/AF. The proportion of type 2 diabetes increased from 3.2% to 6.0% from 2012/2013 to 2020/2021, a relative rate of increase of 9% per two-year period (95% CI 5.9, 12.3; p<0.001). In the two-year period of the COVID-19 pandemic, type 2 diabetes continued to follow the observed trend, with a proportion of 6.0% in 2020-2021 compared with 5.4% in 2018-2019. High variability in the proportion of type 2 diabetes was observed across regions, with the lowest values observed in EU and the highest in NA. A significant increase in the proportion of type 2 diabetes was observed in EU, AU/NZ and NA. The median HbA1c was not uniform and was highest in AS/AF (85 mmol/mol [9.9%]; IQR 55-111 [7.2-12.3%]) and lowest in EU (63 mmol/mol [7.9%]; IQR 48-99 [6.5-11.2%]), and the difference between EU and NA (median value 73 mmol/mol [8.8%]; IQR 50-105 [6.7-11.8%]) was statistically significant (p=0.047). There was also a difference in BMI SD score by region: the lowest median BMI SD score was 2.2 (IQR 1.4-2.7) in AS/AF and the highest was 3.1 (IQR 2.5-3.6) in AU/NZ. CONCLUSIONS/INTERPRETATION: The multinational SWEET data from the years 2012 to 2021 inclusive support recent findings of a worldwide increase in type 2 diabetes in young people, albeit with regional differences. This increase highlights the need for ongoing preventive measures and available advanced treatment modalities worldwide.
引用
- Gesuita R, Eckert AJ, Besançon S, et al. Frequency and clinical characteristics of children and young people with type 2 diabetes at diagnosis from five world regions between 2012 and 2021: data from the SWEET Registry. Diabetologia. 2024. PMID: 39503771. doi:10.1007/s00125-024-06283-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。